REDD implementation for greenhouse gas reduction and climate change mitigation in Hyrcanian forests: a case study of the Kojoor Watershed, Northern Iran

Reducing emissions from deforestation and forest degradation (REDD) is a specific strategy for combating deforestation and forest degradation to alleviate the effects of climate change. In this study, the potential greenhouse gas (GHG) emission reduction resulting from the implementation of a REDD project is estimated. Changes in forest cover throughout the years 1985, 1990, 1995, 2000, 2010, 2015, and 2020 were analyzed using time-series Landsat imagery (TM, ETM + , and OLI) and a random forest algorithm. Multilayer perceptron neural networks were used to model the transition potential of the forest cover, which were then predicted via Markov chain analysis. The change detection analysis revealed two discernible patterns in forest cover dynamics. Between 1985 and 2000, a notable decrease in forest cover was seen, whereas from 2000 to 2020, it significantly increased. The results suggested that the absence of REDD implementation would result in the deforestation of approximately 199,569 hectares of forest cover between 2020 and 2050, leading to the release of 1,995,695 tCO2e of emissions into the atmosphere. However, with the implementation of REDD, these emissions would be reduced to 405,512 tCO2e, effectively preventing the release of 1,590,183 tCO2e of emissions into the upper atmosphere. This study demonstrates that the implementation of REDD projects can be an effective strategy for reducing GHG emissions and mitigating climate change in the Hyrcanian forests.

Sjögren syndrome successfully treated with oxygen-ozone auto-hemotherapy (O2-O3-AHT). a case report

OBJECTIVE

Sjögren syndrome (SS) is an autoimmune disorder, affecting about 16,000 individuals in Italy, yet lacking a standardized therapy protocol and a plain inclusion in the reimbursed healthcare services. This raises many controversial issues about how managing the SS patient, to relief pain and discomfort and improve patients' health and social life. The ozone therapy resulted successful in previous reports, and therefore, it was used in this case report.

CASE PRESENTATION

A 69-years old female outpatient, showing positivity to Schirmer's test, was previously diagnosed as a primary Sjögren syndrome, who later developed an autoimmune thyroiditis and showed the presence of rheumatoid factors. The patient suffered from a marked ocular dryness, subsequently to a purported endothelitis, alongside with fatigue and pain. Laboratory tests showed a positive ANA 1:320 in a speckled pattern with negative anti-SSA and anti-SSB tests. From December 2020 to January 2021 she underwent 2 routes of three sessions of oxygen-ozone autohemotherapy (O2-O3 AHT), as described below and improved, with only 2 sessions, her symptomatology and clinical outcome, as ocular dryness, fatigue and pain, rapidly disappeared.

CONCLUSIONS

The use of ozone in the therapy of SS is a straightforward, affordable and feasible approach to treat primary Sjögren syndrome without significant side effects.

The case of Tehran's urban heat island, Iran: Impacts of urban 'lockdown' associated with the COVID-19 pandemic

The increasing expansion of urban environments with associated transformation of land-cover has led to the formation of urban heat islands (UHI) in many urbanized regions worldwide. COVID-19 related environmental impacts, through reduced urban activities, is worthy of investigation as it may demonstrate human capacity to manage UHI. We aim to establish the thermal impacts associated with COVID-19 induced urban 'lockdown' from 20 March to 20 April 2020 over Tehran. Areal changes in UHI are assessed through Classification and Regression Trees (CART), measured against background synoptic scale temperature changes over the years 1950-2020. Results indicate that monthly T_mean, T_max and T_min values during this time were considerably lower than long-term mean values for the reference period. Although the COVID-19 initiated shutdown led to an identifiable temperature anomaly, we demonstrate that this is not a product of upper atmospheric or synoptic conditions alone. We also show that the cooling effect over Tehran was not spatially uniform, which is likely due to the complexity of land uses such as industrial as opposed to residential. Our findings provide potentially valuable insights and implications for future management of urban heat islands during extreme heat waves that pose a serious threat to human health.

Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection

BACKGROUND

Patients with thalassaemia major depend on blood transfusions. In Italy, up to 80% of thalassaemia patients bear HCV antibodies due to HCV contaminated transfusions before 1990. Thalassaemia patients with HCV infection have high risk of developing HCC. Treatment based on Pegylated-IFN (Peg-IFN) and Ribavirin (RBV) was limited by relevant side effects.

AIM

To evaluate the impact of Sofosbuvir/Ledipasvir (SOF/LDV) fixed dose combination for 12 weeks without RBV, in patients with thalassaemia major and HCV Genotype 1 or 4 (GT1/4).

METHODS

Open label, historically-controlled, nationwide multicentre study in thalassaemia patients including naïve with cirrhosis and prior treatment failure without cirrhosis. SOF/LDV single pill was administered for 12 weeks to 100 patients of whom 16% had cirrhosis. The control group included 96 patients with comparable baseline characteristics treated with Peg-IFN/RBV. The primary end point was sustained virologic response at follow-up week 12 or 24 after IFN-free or Peg-IFN/RBV, respectively.

RESULTS

In the study group, sustained virological response (SVR) was reported in 98% of patients (95% CI 95.3%-100%). Cirrhotic as well as prior treatment failure achieved 100% SVR. In the control group, SVR was 47.9% (95% CI 37.9%-57.9%). Adverse events including fatigue, headache, nausea, decrease in haemoglobin or increase in ferritin levels were rare and significantly less common in the study than in the historical control group.

CONCLUSIONS

In conclusion, SOF/LDV for 12 weeks provides simple, highly effective and safe Peg-IFN/RBV-free treatment for HCV GT1/4 thalassaemia patients. EUDRACT number 2015-002401-1.

S100B protein cord blood levels and development of fetal behavioral states: a study in normal and small-for-dates fetuses

OBJECTIVE

We aimed to determine whether S100B protein levels in cord blood and the development of fetal behavioral states were altered and interrelated in small-for-dates (SFD) fetuses.

METHODS

Umbilical cord blood samples were collected from 12 SFD fetuses with normal umbilical artery (UA) Doppler findings, from six SFD fetuses with abnormal Doppler waveform patterns and from 36 controls matched for gestational age. S100B protein levels were measured by means of a specific radioimmunoassay. Fetal behavioral state recordings were made before delivery by Cesarean section and data were expressed as percentage of quiet sleep coincidence (C1F), of activity state coincidence (C2-4F) and of no coincidence (NOC). Flow velocimetry waveforms were recorded from the uterine artery, UA and fetal middle cerebral artery (MCA).

RESULTS

Mean S100B protein levels in umbilical plasma were significantly higher in the six SFD infants with abnormal prenatal Doppler findings (3.31 +/- 0.65 microg/l) than in SFD infants with normal Doppler findings (1.56 +/- 0.35 microg/l) and in controls (1.23 +/- 0.43 microg/l). Similarly in these fetuses NOC was higher and C2F significantly lower (p < 0.05), but there was no significant difference in C1F. S100B concentrations were correlated with the UA pulsatility index (PI) (r = 0.78, p < 0.01), with the MCA PI (r = -0.78, p < 0.01) and with the UA PI/MCA PI ratio (r = 0.80, p < 0.01). Also, NOC and C2F percentages were correlated with the UA PI (r = 0.61, p < 0.01 and r = -0.61, p < 0.01, respectively), with the MCAPI (r = -0.72, p < 0.001 and r = 0.66, p < 0.01, respectively), and with the UA PI/MCA PI ratio (r = 0.60, p < 0.01 and r = -0.54, p < 0.05, respectively). NOC was also correlated with S100B protein (r = 0.48, p < 0.05); the correlation of S100B protein and C2F almost reached significance (r = -0.47, p < 0.05).

CONCLUSIONS

This study provides evidence of a relationship between a biochemical marker of brain development and/or integrity and the development of fetal behavioral states, offering additional information on brain maturation in normal and high-risk pregnancies.

[Luteal phase support in assisted reproductive cycles using either vaginal (Crinone 8) or intramuscular (Prontogest) progesterone: results of a prospective randomized study]

BACKGROUND

To compare local tolerance and patients compliance to intravaginal and intramuscular progesterone administration.

METHODS

Ninety-nine patients have been randomised to receive either intravaginal Crinone, 90 mg/day (n=51) or intramuscular Prontogest 50 mg/day (n=48) for luteal supplementation in IVF/ICSI cycles. Local and systemic side effects as well as pattern of menstrual bleeding were reported on a self administered questionnaire. Progesterone levels were evaluated pre-treatment, in the mid-luteal phase and the day of pregnancy test.

RESULTS

Patients age, BMI, duration and causes of infertility were comparable in the two treatment groups. All parameters of ovarian response as well as pregnancy rates did not show significative difference in the two groups. A significative larger number of patients assigned to intravaginal support were free from side effects. Furthermore side effects, when reported, resulted significantly more severe in the intramuscular group. In the non pregnant patients menstrual flow appeared significantly earlier in those treated with vaginal progesterone (p<0.001).

CONCLUSIONS

Crinone 8 is a good alternative to parental progesterone for luteal support in ART cycles. It is well tolerated but it is linked to an earlier appearance of menstrual flow in non conceptional cycles.